Amino acid substitutions causing inhibitor resistance in TEM β-lactamases compromise the extended-spectrum phenotype in SHV extended-spectrum β-lactamases

Journal of Antimicrobial Chemotherapy

Volumn 47, Issue 5, 2001, Pages 547-554

  Randegger, Corinne C ^a   Hächler, Herbert ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ARGININE; ASPARAGINE; ASPARTIC ACID; AZTREONAM; BETA LACTAMASE INHIBITOR; CEFALOTIN; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; ISOLEUCINE; METHIONINE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SERINE; SULPERAZON; SULTAMICILLIN; TETRACYCLINE; TICARCILLIN; TIMENTIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG COMBINATION; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; PHENOTYPE;

EID: 17144463688     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/47.5.547     Document Type: Article

References (40)

1. Bush, K., Jacoby, G. A. & Medeiros, A. A. (1995). A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrobial Agents and Chemotherapy 39, 1211-33.
2. MacKenzie, F. M. & Gould, I. M. (1998). Extended spectrum β-lactamases. Journal of Infection 36, 255-8.
3. Fierer, J. & Guiney, D. (1999). Extended-spectrum β-lactamases - a plague of plasmids. Journal of the American Medical Association 281, 563-4.
4. Philippen, A., Labia, R. & Jacoby, G. (1989). Extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 33, 1131-6.
5. Jacoby, G. A. & Medeiros, A. A. (1991). More extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 35, 1697-704.
6. Piroth, L., Aube, H., Doise, J. M. & Vincent-Martin, M. (1998). Spread of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: are β-lactamase inhibitors of therapeutic value? Clinical Infectious Diseases 27, 76-80.
7. Amyes, S. G. B. & Miles, R. S. (1998). Extended-spectrum β-lactamases: the role of inhibitors in therapy. Journal of Antimicrobial Chemotherapy 42, 415-7.
8. Page, J. W., Farmer, T. H. & Elson, S. W. (1989). Hyperproduction of TEM-1 β-lactamase by Escherichia coli strains. Journal of Antimicrobial Chemotherapy 23, 160-1.
9. Wu, P. J., Shannon, K. & Phillips, I. (1995). Mechanisms of hyperproduction of TEM-1 β-lactamase by clinical isolates of Escherichia coli. Journal of Antimicrobial Chemotherapy 36, 927-39.
10. Vedel, G., Belaaouaj, A., Gilly, L., Labia, R., Philippon, A., Nevot, P. et al. (1992). Clinical isolates of Escherichia coli producing TRI β-lactamases: novel TEM-enzymes conferring resistance to β-lactamase inhibitors. Journal of Antimicrobial Chemotherapy 30, 449-62.
11. Jacoby, G. & Bush, K. (2000). Amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant β-lactamases. Lahey Clinic. [On-line.] http://www.lahey.org/studies/ webt.htm (16 October 2000, date last accessed).
12. Sirot, D., Recule, C., Chaibi, E. B., Bret, L., Croize, J., Chanal-Claris, C. et al. (1997). A complex mutant of TEM-1 β-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrobial Agents and Chemotherapy 41, 1322-5.
13. Prinarakis, E. E., Miriagou, V., Tzelepi, E., Gazouli, M. & Tzouvelekis, L. S. (1997). Emergence of an inhibitor-resistant β-lactamase (SHV-10) derived from an SHV-5 variant. Antimicrobial Agents and Chemotherapy 41, 838-40.
14. Randegger, C. C., Keller, A., Irla, M., Wada, A. & Hächler, H. (2000). Contribution of natural amino acid substitutions in SHV extended-spectrum β-lactamases to resistance against various β-lactams. Antimicrobial Agents and Chemotherapy 44, 2759-63.
15. Hanahan, D. (1983). Studies on transformation of Escherichia coli with plasmids. Journal of Molecular Biology 166, 557-80.
16. Nüesch-Inderbinen, M. T., Hächler, H. & Kayser, F. H. (1995). New system based on site-directed mutagenesis for highly accurate comparison of resistance levels conferred by SHV β-lactamases. Antimicrobial Agents and Chemotherapy 39, 1726-30.
17. National Committee for Clinical Laboratory Standards. (1997). Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard M2-A6. NCCLS, Villanova, PA.
18. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
19. Sanger, F., Nicklen, S. & Coulson, A. R. (1977). DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences, USA 74, 5463-7.
20. National Committee for Clinical Laboratory Standards. (1999). Performance Standards for Antimicrobial Susceptibility Testing-Ninth Informational Supplement: M100-S9, Vol. 19, no. 1. NCCLS, Villanova, PA.
21. Chaibi, E. B., Sirot, D., Paul, G. & Labia, R. (1999). Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. Journal of Antimicrobial Chemotherapy 43, 447-58.
22. Nüesch-Inderbinen, M. T., Hächler, H. & Kayser, F. H. (1996). Detection of genes coding for extended-spectrum SHV beta-lactamases in clinical isolates by a molecular genetic method, and comparison with the E test. European Journal of Clinical Microbiology and Infectious Diseases 15, 398-402.
23. Maiti, S. N., Phillips, O. A., Micetich, R. G. & Livermore, D. M. (1998). Beta-lactamase inhibitors: agents to overcome bacterial resistance. Current Medicinal Chemistry 5, 441-56.
24. Rice, L. B., Carias, L. L. & Shlaes, D. M. (1994). In vivo efficacies of β-lactam-β-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 38, 2663-4.
25. Bradford, P. A., Cherubin, C. E., Idemyor, V., Rasmussen, B. A. & Bush, K. (1994). Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals - identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing β-lactamases in a single isolate. Antimicrobial Agents and Chemotherapy 38, 761-6.
26. Rice, L. B., Carias, L. L., Bonomo, R. A. & Shlaes, D. M. (1996). Molecular genetics of resistance to both ceftazidime and β-lactam-β-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to β-lactam therapy. Journal of Infectious Diseases 173, 151-8.
27. Bret, L., Chaibi, E. B., Chanal-Claris, C., Sirot, D., Labia, R. & Sirot, J. (1997). Inhibitor-resistant TEM (IRT) beta-lactamases with different substitutions at position 244. Antimicrobial Agents and Chemotherapy 41, 2547-9.
28. Giakkoupi, P., Tzelepi, E., Legakis, N. J. & Tzouvelekis, L. S. (1999). Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 β-lactamases. Journal of Antimicrobial Chemotherapy 43, 23-9.
29. Giakkoupi, P., Tzelepi, E., Legakis, N. J. & Tzouvelekis, L. S. (1998). Substitution of Arg-244 by Cys or Ser in SHV-1 and SHV-5 β-lactamases confers resistance to mechanism-based inhibitors and reduces catalytic efficiency of the enzymes. FEMS Microbiology Letters 160, 49-54.
30. Giakkoupi, P., Miriagou, V., Gazouli, M., Tzelepi, E., Legakis, N. J. & Tzouvelekis, L. S. (1998). Properties of mutant SHV-5 β-lactamases constructed by substitution of isoleucine or valine for methionine at position 69. Antimicrobial Agents and Chemotherapy 42, 1281-3.
31. Lin, S., Thomas, M., Mark, S., Anderson, V. & Bonomo, R. A. (1999). OHIO-1 beta-lactamase mutants: the Arg244Ser mutant and resistance to beta-lactams and beta-lactamase inhibitors. Biochimica et Biophysica Acta Protein Structure and Molecular Enzymology 1432, 125-36.
32. Lin, S., Thomas, M., Shlaes, D. M., Rudin, S. D., Knox, J. R., Anderson, V. et al. (1998). Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 β-lactamase, an SHV-family class A enzyme. Biochemical Journal 333, 395-400.
33. Bonomo, R. A., Knox, J. R., Rudin, S. D. & Shlaes, D. M. (1997). Construction and characterization of an ohio-1 beta-lactamase bearing Met69lle and Gly238Ser mutations. Antimicrobial Agents and Chemotherapy 41, 1940-3.
34. Stapleton, P. D., Shannon, K. P. & French, G. L. (1999). Construction and characterization of mutants of the TEM-1 β-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to β-lactamase inhibitors. Antimicrobial Agents and Chemotherapy 43, 1881-7.
35. Huletsky, A., Knox, J. R. & Levesque, R. C. (1993). Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type β-lactamases probed by site-directed mutagenesis and 3-dimensional modeling. Journal of Biological Chemistry 268, 3690-7.
36. Imtiaz, U., Manavathu, E. K., Mobashery, S. & Lerner, S. A. (1994). Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 β-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime. Antimicrobial Agents and Chemotherapy 38, 1134-9.
37. Vakulenko, S. B., Geryk, B., Kotra, L. P., Mobashery, S. & Lerner, S. A. (1998). Selection and characterization of β-lactam-β-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 β-lactamase gene. Antimicrobial Agents and Chemotherapy 42, 1542-8.
38. Du Bois, S. K., Marriott, M. S. & Amyes, S. G. B. (1995). TEM- and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and function. Journal of Antimicrobial Chemotherapy 35, 7-22.
39. Thomson, C. J. & Amyes, S. G. (1995). Back mutations to the TEM-1 β-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid. Journal of Medical Microbiology 42, 429-32.
40. Vakulenko, S. B., Mobashery, S. & Lerner, S. A. (1999). Extended-spectrum (E-S), inhibitor-resistant mutants of the TEM-1 β-lactamase. In Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract 2048, p. 137. American Society for Microbiology, Washington, DC.